HIGHLIGHTS
SUMMARY
Tranexamic acid (TXA) the authors were able to demonstrate that inhibition of the fibrinolytic cascade results in reduced infection rates in non-diabetic patients. The authors used a similar approach as previously harnessed in the ATACAS trial to characterise the cellular immune_response in patients undergoing orthopaedic (hip or knee replacement) surgery randomised to TXA, as part of the "Tranexamic Acid in Lower Limb Arthroplasty" (TALLAS) feasibility study. Technical issues with the CD3 stain led to a complete loss in signal for this marker, critical for T_cell identification, which is why T_cells were excluded from . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.